|
Powered by Cell Signaling Technology |
Site Information |
---|
LATkAARksAPsTGG SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 18545330 |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Disease tissue studied: | |
Relevant cell line - cell type - tissue: |
References | |
---|---|
Abshiru NA, et al. (2020) Targeted detection and quantitation of histone modifications from 1,000 cells. PLoS One 15, e0240829
33104722 Curated Info |
|
Guo A, et al. (2014) Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13, 372-87
24129315 Curated Info |
|
Bremang M, et al. (2013) Mass spectrometry-based identification and characterisation of lysine and arginine methylation in the human proteome. Mol Biosyst 9, 2231-47
23748837 Curated Info |
|
Mulhern D (2011) CST Curation Set: 13061; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m2K
Curated Info |
|
Possemato A (2009) CST Curation Set: 8356; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m2K
Curated Info |
|
Possemato A (2009) CST Curation Set: 5995; Year: 2009; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m2K
Curated Info |
|
Possemato A (2008) CST Curation Set: 3750; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m2K
Curated Info |
|
Garcia BA, et al. (2005) Modifications of human histone H3 variants during mitosis. Biochemistry 44, 13202-13
16185088 Curated Info |